» Articles » PMID: 39853441

Patients with Antiphospholipid Antibodies Preferentially Seek Health Information from Physicians: a Cross-sectional Online Patient Quantitative Survey

Overview
Journal Rheumatol Int
Date 2025 Jan 24
PMID 39853441
Authors
Affiliations
Soon will be listed here.
Abstract

Little is known about how patients with antiphospholipid syndrome (APS) or antiphospholipid antibodies (aPL) access and trust health information. This research aimed to: describe the sources of information most frequently accessed/trusted by patients with APS/aPL; identify if individuals with APS/aPL perceived their health had been negatively impacted by various sources and document obstacles to accessing health information. Patients meeting Revised Sapporo Criteria for APS or with ≥1 positive aPL on ≥2 occasions were recruited to an online survey regarding their health information use at diagnosis and within 6 months preceding survey completion. McNemar tests were used to compare percentages accessing and trusting each source at diagnosis/currently. 69 patients completed the survey; 88.4% were female, mean age was 47.4 years (SD 15.1). The sources most frequently accessed at diagnosis and currently were rheumatologists/lupus specialists, hematologists, and family physicians, yet patients accessed family physicians (47.8% vs. 31.9%, difference -15.9%, 95% CI - 29.2%, -2.7%) and hematologists (47.8% vs. 31.9%, difference -15.9%, 95% CI -31.1%, -0.8%) less frequently from diagnosis to currently. The most trusted sources at diagnosis and currently were rheumatologists/lupus specialists (82.6% vs. 92.8%) and family physicians (66.7% vs. 68.1%). Few respondents reported negative impacts from advocacy organizations (4.4%), websites (5.8%) and social media (4.4%). 20.3% reported challenges communicating with healthcare providers. Patients with aPL/APS preferentially seek health information from and trust their physicians. However, 20.3% of patients felt communication with healthcare providers was an obstacle to accessing information. There is a need for enhanced patient-physician communication.

References
1.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M . The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023; 75(10):1687-1702. DOI: 10.1002/art.42624. View

2.
Tektonidou M, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N . EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78(10):1296-1304. PMC: 11034817. DOI: 10.1136/annrheumdis-2019-215213. View

3.
Noureldine M, Nour-Eldine W, Khamashta M, Uthman I . Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. Semin Arthritis Rheum. 2018; 48(5):860-866. DOI: 10.1016/j.semarthrit.2018.08.004. View

4.
Skeith L, Rodger M, Bates S, Gonsalves C, Karovitch A, Taylor T . "Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. Thromb Haemost. 2021; 121(10):1353-1360. DOI: 10.1055/a-1366-9261. View

5.
Klein Haneveld M, Lemmen C, Brunekreef T, Bijl M, Jansen A, de Leeuw K . Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands. Rheumatol Adv Pract. 2020; 4(2):rkaa021. PMC: 7474856. DOI: 10.1093/rap/rkaa021. View